Tumor necrosis factor as a pharmacological target

Area of Science:

• Immunology
• Molecular Biology
• Oncology

Background:

• Tumor necrosis factor (TNF) was identified as a macrophage-derived mediator capable of tumor necrosis and killing tumor cells.
• Early clinical trials revealed significant toxicity, limiting its use as an anticancer agent.
• TNF was also identified as cachectin, a mediator of sepsis-induced cachexia.

Purpose of the Study:

• To review the multifaceted roles of TNF in disease.
• To explore the evolution of TNF research from oncology to inflammatory diseases.
• To discuss the potential for future therapeutic applications of TNF knowledge.

Main Methods:

• Literature review and synthesis of existing research on TNF.
• Analysis of historical and current clinical trial data.
• Exploration of molecular mechanisms underlying TNF-induced cell death.

Main Results:

• TNF's dual role in cancer and sepsis was established, highlighting its inflammatory properties.
• Despite initial setbacks in sepsis trials, TNF was confirmed as a critical inflammatory mediator.
• The development of anti-TNF therapies (receptors, antibodies) for inflammatory conditions like rheumatoid arthritis and Crohn's disease.

Conclusions:

• TNF is a pivotal mediator in inflammatory responses and sepsis.
• Understanding TNF's cell death mechanisms may offer future strategies to improve its therapeutic index in cancer.
• Targeting TNF has led to successful treatments for autoimmune and inflammatory diseases.